Citius Oncology Reports 78% Surge in New Institutions Ordering LYMPHIR, Signaling Strong Commercial Launch

summarizeSummary

Citius Oncology's LYMPHIR launch is gaining traction: new institutional accounts jumped 78% QoQ, vial orders rose 31%, and near-universal payer coverage is secured. This commercial progress is critical for a company that recently faced going-concern doubts.

check_boxKey Events · Product Development and Regulatory · CTOR

• 78% Surge in New Institutional Accounts

  New institutions ordering LYMPHIR increased 78% quarter over quarter, with total institutional vial orders rising 31% during the same period.

• LYMPHIR Now in 42 Institutions

  The therapy is available in 42 academic oncology centers, NCCN institutions, and community infusion centers, with more than 20 additional institutions expected in the current quarter.

• Near-Universal Payer Coverage Secured

  LYMPHIR has achieved near-universal payer coverage, removing a key reimbursement barrier and expanding patient access.

• Year-End Target: 100 Priority Institutions

  Management targets formulary inclusion with 100 priority institutions by year-end, supported by an expanded commercial and medical affairs team.

auto_awesomeAnalysis · CTOR · Life Sciences

Citius Oncology disclosed a 78% quarter-over-quarter increase in new institutional accounts ordering LYMPHIR, its recently launched CTCL therapy. Vial orders rose 31%, and the drug is now available in 42 institutions with near-universal payer coverage. This commercial traction directly addresses the going-concern risk flagged in the May 10-Q — revenue generation is the critical path to survival. The company also guided to 100 priority institutions by year-end, suggesting a credible ramp. For a micro-cap biotech with a $61M market cap and a recent history of dilutive financings, these early launch metrics are a material positive signal that the product is gaining real-world adoption.